Baker is a clinical centre in cardiovascular medicine with a special focus on arteriosclerosis and population-based studies. It is an independent, internationally renowned medical research facility with over 85 years of history. Work at the institute extends from the laboratory to broad community studies with a focus on diagnosis, prevention and treatment of diabetes and cardiovascular disease. Over 700 scientists are working at Baker with the aim of translating laboratory findings into new approaches for the prevention, treatment and care of cardiovascular diseases.
Within sysVASC, Baker will contribute clinical datasets and samples from large population based cohorts, miRNAomics dataset, as well as animal models.Karlheinz Peter MD, PhD
Karlheinz Peter is associate director and department head at Baker. In addition, he is a professor of Medicine & Immunology at Monash University, and senior interventional cardiologist at the Alfred Hospital in Melbourne, Australia. His basic science and clinical work focuses on improving the diagnostic and therapeutic approaches in order to prevent and treat myocardial infarction. Karlheinz Peterhas also been awarded a highly competitive Future Fellowship from the Australian Research Council based on his innovative work.
2 von zur Muhlen C., et al. (2009). Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Prot Res.8, 335-45.
3 Habersberger J., et al. (2012) Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res. 96, 64-72.